Biochrom, Gilson Sign ELISA Distribution Agreement
News Jun 10, 2014
The partnership combines the strength of the EZ Read range of microplate readers from Biochrom, with Gilson’s innovative line of liquid handling systems. Used together the flexible offering enables scientists to easily automate their absorbance assays including ELISA, total protein and cell viability.
Biochrom created the EZ Read microplate reader range by matching its expertise in absorbance measurement with requests from scientists and technicians to make their experimental workflow easier and more effective. Gilson has incorporated its vast knowledge of liquid transfer techniques into a wide range of automated liquid handlers.
Tristana von Will, Global Product Marketing Manager at Biochrom, commented: “Gilson is a leader in liquid handling systems and we are delighted to be combining the heritage and expertise of both companies to co-sell our product ranges. Researchers and technicians will be very familiar with both the Biochrom and Gilson brands, but together we can further streamline experimental workflows for our customers.”
Ronan Herry, European Marketing Director at Gilson International BV, stated:” The Biochrom range of EZ Read Microplate readers fits very well with our range of liquid handling products, either for those customers who require manual or electronic multichannel pipettes from the PIPETMAN range or for those customers that would like to automate their lab work flows. The Gilson PIPETMAX comes at a size and price that is accessible to any lab and takes away the stress and strain of manual pipetting for ELISA and Bradford type assays while improving reproducibility. Adding the Biochrom range now enables Gilson to offer a complete applications solution for our customers”.
Could This Be a "Silver Bullet" for Preventing and Treating Colon Cancer?News
A team of scientists targeted the gene CtBP with a drug known as HIPP (2-hydroxy-imino phenylpyruvic acid) and were able to reduce the development of pre-cancerous polyps by half.READ MORE
Shedding Light on How Tumors Become Resistant to ImmunotherapyNews
Researchers have now found that in skin cutaneous melanoma an epigenetic control protein is key to the development of immunotherapy resistance.READ MORE
Comments | 0 ADD COMMENT
6th Edition of International Conference on Pharmacognosy and Medicinal Plants
Apr 16 - Apr 17, 2018
10th Edition of International Conference on Structural Biology 2018
Mar 15 - Mar 17, 2018